Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.

Ducks congenitally infected with duck hepatitis B virus (DHBV) were treated with the guanosine analogue, ganciclovir, and the effect on serum and intrahepatic expression of DHBV DNA and viral proteins was examined. After 21 days of ganciclovir treatment, a substantial reduction in viraemia occurred; in contrast, the level of circulating DHBV surface antigen was unchanged. Ganciclovir therapy also substantially reduced the level of DHBV DNA replicative intermediates and the expression of viral core and surface antigen in hepatocytes. However, despite the antiviral treatment some liver cells, including the bile duct epithelial cells and putative oval cells, maintained their intense staining for the viral proteins. Furthermore, DHBV-infected cells in extrahepatic sites such as the pancreas, kidney and spleen were also unaffected by ganciclovir treatment. These results suggest that monotherapy with nucleoside analogues is unlikely to eliminate chronic hepadnaviral infection, and antiviral programs should be designed to target all cell populations infected by the virus.

[1]  P. Angus,et al.  Combination antiviral therapy controls severe post‐liver transplant recurrence of hepatitis B virus infection , 1993, Journal of gastroenterology and hepatology.

[2]  S. Locarnini,et al.  The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. , 1993, Antiviral research.

[3]  J. Travis The search for liver stem cells picks up. , 1993, Science.

[4]  J. Hoofnagle,et al.  Long-term remission of chronic hepatitis B after alpha-interferon therapy. , 1991, Annals of internal medicine.

[5]  S. Bowden,et al.  Inhibition of Duck Hepatitis B Virus Replication in vivo by the Nucleoside Analogue Ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] Guanine) , 1991 .

[6]  A. Lok,et al.  Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver. , 1991, Gastroenterology.

[7]  D. Ganem,et al.  Assembly of hepadnaviral virions and subviral particles. , 1991, Current topics in microbiology and immunology.

[8]  S. Locarnini,et al.  Effect of Phyllanthus amarus on duck hepatitis B virus replication in vivo , 1990, Journal of medical virology.

[9]  M. Omata Significance of extrahepatic replication of hepatitis B virus , 1990, Hepatology.

[10]  C. Burrell,et al.  Serological analysis of duck hepatitis B virus infection. , 1990, Virus research.

[11]  I. Gust,et al.  Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B Virus in vitro using conventional antiviral agents and supercoiled‐DNA active compounds , 1990, Journal of medical virology.

[12]  S. Locarnini,et al.  Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model , 1990, Journal of medical virology.

[13]  J. Summers,et al.  In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. , 1990, Virology.

[14]  N. Jones,et al.  Reduced duck hepatitis B virus viraemia in ducklings coinfected with the immunodepressive reticuloendotheliosis virus , 1990, Journal of medical virology.

[15]  S. Locarnini,et al.  INHIBITION OF HBV DNA REPLICATION BY GANCICLOVIR IN PATIENTS WITH AIDS , 1989, The Lancet.

[16]  G. Gasbarrini,et al.  A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy , 1989, Hepatology.

[17]  J. Cullen,et al.  A Sequential Histologic and Immunohistochemical Study of Duck Hepatitis B Virus Infection in Pekin Ducks , 1989, Veterinary pathology.

[18]  J. Hoofnagle,et al.  Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B , 1988 .

[19]  Y. Cossart,et al.  Virus-liver cell interactions in duck hepatitis B virus infection. A study of virus dissemination within the liver. , 1988, Gastroenterology.

[20]  C. Rogler,et al.  Insulinlike growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers , 1988, Journal of virology.

[21]  C. Ferrari,et al.  Cellular immune response to hepatitis B virus antigens. An overview. , 1988, Journal of hepatology.

[22]  H. Schlicht,et al.  The duck hepatitis B virus pre-C region encodes a signal sequence which is essential for synthesis and secretion of processed core proteins but not for virus formation , 1987, Journal of virology.

[23]  J. Hoofnagle,et al.  Chronic type B hepatitis and the “healthy” Hbsag carrier state , 1987, Hepatology.

[24]  J. Summers,et al.  Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells , 1986, Cell.

[25]  A. Zuckerman,et al.  Taxonomic classification of human hepatitis B virus. , 1986, Intervirology.

[26]  O. Yokosuka,et al.  Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: Analysis of intrahepatic replicative hepatitis B virus DNA , 1985, Hepatology.

[27]  A. Haase,et al.  Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Adler,et al.  A POMONA SEROGROUP‐SPECIFIC, AGGLUTINATING ANTIGEN IN LEPTOSPIRA, IDENTIFIED BY MONOCLONAL ANTIBODIES , 1983, Pathology.

[29]  J. Summers,et al.  Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate , 1982, Cell.

[30]  Y. Naito,et al.  Cytosol 5'-nucleotidase from chicken liver. Purification and some properties. , 1976, Biochimica et biophysica acta.